A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)

Key facts

Sponsor

Akebia Therapeutics

Intervention

Praliciguat(drug)

Enrollment

60 enrolled

Eligibility

18 years · All sexes

Timeline

2025 – 2028

Study locations (8)

• Investigator Site #2, Chula Vista, California, United States
• Investigator Site #6, Coral Springs, Florida, United States
• Investigator Site #7, Miami, Florida, United States
• Investigator Site #8, Orlando, Florida, United States
• Investigator Site # 1, Lawrenceville, Georgia, United States
• Investigator Site #3, Chicago, Illinois, United States
• Investigator Site #4, Chattanooga, Tennessee, United States
• Investigator Site #5, Arlington, Texas, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Idiopathic multidrug-resistant nephrotic syndrome

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT06664814
  An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis
  National Human Genome Research Institute (NHGRI)
• RECRUITINGPHASE3NCT07220083
  A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
  Boehringer Ingelheim
• RECRUITINGPHASE2NCT06500702
  A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
  Sanofi
• RECRUITINGPHASE1, PHASE2NCT06090227
  AMPK-activation by Metformin in FSGS: AMP-FSGS
  Yale University
• RECRUITINGNCT05650619
  Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
  University of Michigan
• RECRUITINGNANCT04065438
  Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System
  Kaneka Medical America LLC
• ACTIVE NOT RECRUITINGPHASE3NCT03493685
  Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
  Travere Therapeutics, Inc.
• RECRUITINGNANCT02235857
  Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
  Kaneka Medical America LLC

See all trials for Idiopathic multidrug-resistant nephrotic syndrome →